217 related articles for article (PubMed ID: 11673492)
1. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs.
Ballas ZK; Krieg AM; Warren T; Rasmussen W; Davis HL; Waldschmidt M; Weiner GJ
J Immunol; 2001 Nov; 167(9):4878-86. PubMed ID: 11673492
[TBL] [Abstract][Full Text] [Related]
2. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.
Ballas ZK; Rasmussen WL; Krieg AM
J Immunol; 1996 Sep; 157(5):1840-5. PubMed ID: 8757300
[TBL] [Abstract][Full Text] [Related]
3. Modulation of NK cell activity by CpG oligodeoxynucleotides.
Ballas ZK
Immunol Res; 2007; 39(1-3):15-21. PubMed ID: 17917052
[TBL] [Abstract][Full Text] [Related]
4. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
5. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
[TBL] [Abstract][Full Text] [Related]
6. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides.
Kawarada Y; Ganss R; Garbi N; Sacher T; Arnold B; Hämmerling GJ
J Immunol; 2001 Nov; 167(9):5247-53. PubMed ID: 11673539
[TBL] [Abstract][Full Text] [Related]
7. Structural characterization of the inhibitory DNA motif for the type A (D)-CpG-induced cytokine secretion and NK-cell lytic activity in mouse spleen cells.
Lenert P; Rasmussen W; Ashman RF; Ballas ZK
DNA Cell Biol; 2003 Oct; 22(10):621-31. PubMed ID: 14611683
[TBL] [Abstract][Full Text] [Related]
8. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma.
Wooldridge JE; Ballas Z; Krieg AM; Weiner GJ
Blood; 1997 Apr; 89(8):2994-8. PubMed ID: 9108420
[TBL] [Abstract][Full Text] [Related]
9. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.
Hartmann G; Weeratna RD; Ballas ZK; Payette P; Blackwell S; Suparto I; Rasmussen WL; Waldschmidt M; Sajuthi D; Purcell RH; Davis HL; Krieg AM
J Immunol; 2000 Feb; 164(3):1617-24. PubMed ID: 10640783
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive and efficient transdermal delivery of CpG-oligodeoxynucleotide for cancer immunotherapy.
Kigasawa K; Kajimoto K; Nakamura T; Hama S; Kanamura K; Harashima H; Kogure K
J Control Release; 2011 Mar; 150(3):256-65. PubMed ID: 21256903
[TBL] [Abstract][Full Text] [Related]
11. Distinct CpG oligonucleotide sequences activate human gamma delta T cells via interferon-alpha/-beta.
Rothenfusser S; Hornung V; Krug A; Towarowski A; Krieg AM; Endres S; Hartmann G
Eur J Immunol; 2001 Dec; 31(12):3525-34. PubMed ID: 11745372
[TBL] [Abstract][Full Text] [Related]
12. Treg depletion followed by intracerebral CpG-ODN injection induce brain tumor rejection.
Jarry U; Donnou S; Vincent M; Jeannin P; Pineau L; Fremaux I; Delneste Y; Couez D
J Neuroimmunol; 2014 Feb; 267(1-2):35-42. PubMed ID: 24369298
[TBL] [Abstract][Full Text] [Related]
13. Structure-efficacy relationships of immunostimulatory activity of CpG-containing oligodeoxynucleotides on mouse spleen cells.
Du HY; Xia SY; Song HF; Li N; Shang MM; Zou J; Wang QQ; Ou L; Sun X; Ji AG; Tang ZM
Acta Pharmacol Sin; 2007 Oct; 28(10):1637-44. PubMed ID: 17883951
[TBL] [Abstract][Full Text] [Related]
14. CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.
Hiramatsu K; Serada S; Kobiyama K; Nakagawa S; Morimoto A; Matsuzaki S; Ueda Y; Fujimoto M; Yoshino K; Ishii KJ; Enomoto T; Kimura T; Naka T
Cancer Sci; 2015 Oct; 106(10):1474-8. PubMed ID: 26498112
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
16. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
[TBL] [Abstract][Full Text] [Related]
17. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
Davis HL; Weeratna R; Waldschmidt TJ; Tygrett L; Schorr J; Krieg AM
J Immunol; 1998 Jan; 160(2):870-6. PubMed ID: 9551923
[TBL] [Abstract][Full Text] [Related]
18. Immunostimulatory and anti-neoplasm effects of a novel palindrome CpG oligodeoxynucleotide in mice.
Du HY; Dong LH; Zhao BJ; Fu J; Wang QQ; Chen F; Ou L; Li N; Sun X; Tang ZM; Song HF
Acta Pharmacol Sin; 2012 Aug; 33(8):1047-54. PubMed ID: 22728711
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice.
Gramzinski RA; Doolan DL; Sedegah M; Davis HL; Krieg AM; Hoffman SL
Infect Immun; 2001 Mar; 69(3):1643-9. PubMed ID: 11179339
[TBL] [Abstract][Full Text] [Related]
20. Induction of interleukin-6 and interleukin-12 in bovine B lymphocytes, monocytes, and macrophages by a CpG oligodeoxynucleotide (ODN 2059) containing the GTCGTT motif.
Zhang Y; Shoda LK; Brayton KA; Estes DM; Palmer GH; Brown WC
J Interferon Cytokine Res; 2001 Oct; 21(10):871-81. PubMed ID: 11711000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
